Protecting IP in plant-based ‘meat-substitutes’
Innovation in the plant-based meat sector is aiming to help to solve some of the problems associated with animal-meat production.
Protecting IP in lab-grown organs – organoids
Lab-grown miniature organs (also known as organoids) is a technology area that has the potential to significantly lower costs and failure rates in drug development, and to improve safety.
Inside Green Innovation: Progress Report 2021
What can patent data reveal about global progress in green innovation, and what might be achieved in years to come?
The Greenshoots Podcast by Appleyard Lees – episode 20: Doctrine of equivalents and its impact on patent infringement assessment in the UK
In 2017, the UK Supreme Court’s judgement of Actavis v Eli Lilly created significant change to the way patent infringement is assessed in the UK by introducing a formal doctrine of equivalents. Four years on, Appleyard Lees partners and patent attorneys Adam Tindall and David Walsh, and senior associate and patent attorney Chris Mason discuss […]
Sources of funding for innovation, and innovators, in the wake of COVID-19 and beyond
Sourcing funding for innovation is currently at the forefront of many businesses’ agenda in response to the current global pandemic. While it is an uncertain time for many, there are still plenty of funding opportunities available for innovation-led businesses. In this article we highlight some of the funding opportunities available to small businesses, larger businesses […]
Akebia and Fibrogen – Lord Justice Arnold applies “Doctrine of Equivalents”
In this judgment at the High Court, Lord Justice Arnold stepped down from the Court of Appeal to the High Court to hear the case. His findings on infringement may be an indication of Arnold’s desire to set some practical limits on the first and third Actavis equivalence questions. In particular, he applies a rigorous […]
